FOXK2 facilitates the airway remodeling during chronic asthma by promoting glycolysis in a SIRT2 ‐dependent manner

Abstract Asthma is a chronic pulmonary disease with the worldwide prevalence. The structural alterations of airway walls, termed as “airway remodeling”, are documented as the core contributor to the airway dysfunction during chronic asthma. Forkhead box transcription factor FOXK2 is a critical regulator of glycolysis, a metabolic reprogramming pathway linked to pulmonary fibrosis. However, the role of FOXK2 in asthma waits further explored. In this study, the chronic asthmatic mice were induced via ovalbumin (OVA) sensitization and repetitive OVA challenge. FOXK2 was upregulated in the lungs of OVA mice and downregulated after adenovirus‐mediated FOXK2 silencing. The lung inflammation, peribronchial collagen deposition, and glycolysis in OVA mice were obviously attenuated after FOXK2 knockdown. Besides, the expressions of FOXK2 and SIRT2 in human bronchial epithelial cells (BEAS‐2B) were increasingly upregulated upon TGF‐β1 stimulation and downregulated after FOXK2 knockdown. Moreover, the functional loss of FOXK2 remarkably suppressed TGF‐β1‐induced epithelial‐mesenchymal transition (EMT) and glycolysis in BEAS‐2B cells, as manifested by the altered expressions of EMT markers and glycolysis enzymes. The glycolysis inhibitor 2‐deoxy‐d‐glucose (2‐DG) inhibited the EMT in TGF‐β1‐induced cells, making glycolysis a driver of EMT. The binding of FOXK2 to SIRT2 was validated, and SIRT2 overexpression blocked the FOXK2 knockdown‐mediated inhibition of EMT and glycolysis in TGF‐β1‐treated cells, which suggests that FOXK2 regulates EMT and glycolysis in TGF‐β1‐treated cells in a SIRT2‐dependnet manner. Collectively, this study highlights the protective effect of FOXK2 knockdown on airway remodeling during chronic asthma.